Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Brennan Daniel J. | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 795 | $503.47 | $400,258.65 | 795Direct | Form 4 filed 22 Oct 2026, on sec.gov (opens in a new tab)Filed 22 Oct 2026 | |
| Malik Fady Ibraham | EVP Research & Development | CYTOKINETICS INCCYTK | SellS · Open-market or private sale | 3,500 | $64.01 | $224,035 | 153,902Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Malik Fady Ibraham | EVP Research & Development | CYTOKINETICS INCCYTK | OtherM · Option or derivative exercised or converted | 3,500 | $7.80 | $27,300 | 157,402Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Sulzberger Gabrielle | Director | ELI LILLY & CoLLY | OtherA · Grant or award from the company | 3.9976 | $1,240.34 | $4,958.38 | 3,016.4449Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| LUCIANO JUAN R | Director | ELI LILLY & CoLLY | OtherA · Grant or award from the company | 12.8325 | $1,240.34 | $15,916.66 | 16,969.6463Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Fyrwald J Erik | Director | ELI LILLY & CoLLY | OtherA · Grant or award from the company | 7.9951 | $1,240.34 | $9,916.64 | 75,544.1259Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Alvarez Ralph | Director | ELI LILLY & CoLLY | OtherA · Grant or award from the company | 10.0107 | $1,240.34 | $12,416.67 | 55,848.2299Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Wysenski Nancy | Director | CYTOKINETICS INCCYTK | OtherA · Grant or award from the company | 97 | $63.92 | $6,200.24 | 34,089Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Kaye Edward M. MD | Director | CYTOKINETICS INCCYTK | OtherA · Grant or award from the company | 195 | $63.92 | $12,464.40 | 10,629Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Harrington Robert Arthur | Director | CYTOKINETICS INCCYTK | OtherA · Grant or award from the company | 195 | $63.92 | $12,464.40 | 22,127Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| Daly James M | Director | CYTOKINETICS INCCYTK | OtherA · Grant or award from the company | 195 | $63.92 | $12,464.40 | 3,585Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| WIERENGA WENDELL | Director | CYTOKINETICS INCCYTK | OtherA · Grant or award from the company | 97 | $63.92 | $6,200.24 | 35,660Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| HENDERSON JOHN T | Director | CYTOKINETICS INCCYTK | OtherA · Grant or award from the company | 352 | $63.92 | $22,499.84 | 78,712Direct | Form 4 filed 20 Oct 2026, on sec.gov (opens in a new tab)Filed 20 Oct 2026 | |
| WILSON JAMES N | Director | CORCEPT THERAPEUTICS INCCORT | SellS · Open-market or private sale | 300 | $116.2967 | $34,889.01 | 1,054,543Indirect, James N. Wilson and Pamela D. Wilson Trust | Form 4 filed 16 Oct 2026, on sec.gov (opens in a new tab)Filed 16 Oct 2026 | |
| WILSON JAMES N | Director | CORCEPT THERAPEUTICS INCCORT | SellS · Open-market or private sale | 3,046 | $115.3895 | $351,476.42 | 1,054,843Indirect, James N. Wilson and Pamela D. Wilson Trust | Form 4 filed 16 Oct 2026, on sec.gov (opens in a new tab)Filed 16 Oct 2026 | |
| WILSON JAMES N | Director | CORCEPT THERAPEUTICS INCCORT | SellS · Open-market or private sale | 6,654 | $114.4751 | $761,717.32 | 1,057,889Indirect, James N. Wilson and Pamela D. Wilson Trust | Form 4 filed 16 Oct 2026, on sec.gov (opens in a new tab)Filed 16 Oct 2026 | |
| Hoge Stephen | President | Moderna, Inc.MRNA | SellS · Open-market or private sale | 39,145 | $220.72 | $8,640,084.40 | 1,636,565Direct | Form 4 filed 16 Oct 2026, on sec.gov (opens in a new tab)Filed 16 Oct 2026 | |
| Hoge Stephen | President | Moderna, Inc.MRNA | OtherM · Option or derivative exercised or converted | 76,452 | $12.21 | $933,478.92 | 1,675,710Direct | Form 4 filed 16 Oct 2026, on sec.gov (opens in a new tab)Filed 16 Oct 2026 | |
| MURPHY ANDREW J | Co-Chief Scientific Officer | REGENERON PHARMACEUTICALS, INC.REGN | SellS · Open-market or private sale | 50 | $781.47 | $39,073.50 | 47,833Direct | Form 4 filed 15 Oct 2026, on sec.gov (opens in a new tab)Filed 15 Oct 2026 | |
| MURPHY ANDREW J | Co-Chief Scientific Officer | REGENERON PHARMACEUTICALS, INC.REGN | SellS · Open-market or private sale | 463 | $780.63 | $361,431.69 | 47,883Direct | Form 4 filed 15 Oct 2026, on sec.gov (opens in a new tab)Filed 15 Oct 2026 | |
| MURPHY ANDREW J | Co-Chief Scientific Officer | REGENERON PHARMACEUTICALS, INC.REGN | SellS · Open-market or private sale | 380 | $779.59 | $296,244.20 | 48,346Direct | Form 4 filed 15 Oct 2026, on sec.gov (opens in a new tab)Filed 15 Oct 2026 | |
| MURPHY ANDREW J | Co-Chief Scientific Officer | REGENERON PHARMACEUTICALS, INC.REGN | SellS · Open-market or private sale | 454 | $778.64 | $353,502.56 | 48,726Direct | Form 4 filed 15 Oct 2026, on sec.gov (opens in a new tab)Filed 15 Oct 2026 | |
| MURPHY ANDREW J | Co-Chief Scientific Officer | REGENERON PHARMACEUTICALS, INC.REGN | SellS · Open-market or private sale | 38 | $777.76 | $29,554.88 | 49,180Direct | Form 4 filed 15 Oct 2026, on sec.gov (opens in a new tab)Filed 15 Oct 2026 | |
| MURPHY ANDREW J | Co-Chief Scientific Officer | REGENERON PHARMACEUTICALS, INC.REGN | SellS · Open-market or private sale | 66 | $776.31 | $51,236.46 | 49,218Direct | Form 4 filed 15 Oct 2026, on sec.gov (opens in a new tab)Filed 15 Oct 2026 | |
| MURPHY ANDREW J | Co-Chief Scientific Officer | REGENERON PHARMACEUTICALS, INC.REGN | SellS · Open-market or private sale | 376 | $775.46 | $291,572.96 | 49,284Direct | Form 4 filed 15 Oct 2026, on sec.gov (opens in a new tab)Filed 15 Oct 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.